Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Neoadjuvant chemotherapy is associated with a high rate of perioperative blood transfusion at the time of interval cytoreductive surgery

Fig. 2

Kaplan-Meier Analysis of patients undergoing interval cytoreduction after NACT. Median time to progression was compared between patients who received perioperative blood transfusion (red line) versus those who did not (blue line). PFS = 7.6 months for transfusion group; PFS = 9.44 no transfusion group. Data were analyzed using the log-rank test

Back to article page
\